Skip to content
The Policy VaultThe Policy Vault

Afinitor DisperzCareFirst (Caremark)

Classic Hodgkin lymphoma (relapsed or refractory)

Initial criteria

  • Diagnosis of relapsed or refractory classic Hodgkin lymphoma
  • Requested as single agent

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months